<DOC>
	<DOCNO>NCT01766076</DOCNO>
	<brief_summary>We hypothesise atorvastatin change immune activation among HAART-treated adult suboptimal cluster cell differentiation 4 ( CD4 ) recovery 25 %</brief_summary>
	<brief_title>Atorvastatin HAART Suboptimal Responders</brief_title>
	<detailed_description>The investigator previously show 40 % HAART-treated adult suboptimal CD4 recovery despite viral suppression . The investigator also show immune activation exhaustion significantly high among patient exhibit satisfactory rise CD4 count despite viral suppression ( suboptimal responder ) ; compare counterpart viral suppression satifactory CD4 count recovery ( optimal responder ) . Given atorvastatin change immune activation pilot study , large study do understand effect CD4 count increase among suboptimal responder .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>List inclusion Criteria : HIVinfected adult antiretroviral therapy least 6 year sustain viral suppression ( viral load &lt; 400 copy ) , CD4 increase 300 cell ( difference current baseline CD4 count ) . List exclusion Criteria : History opportunistic infection within previous six month , Pregnancy , History myositis , History ingestion lipidlowering agent baseline visit , Use therapeutic agent know substantial drugdrug interaction statin , individual PIcontaining HAART</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>immune activation</keyword>
	<keyword>antiretroviral therapy</keyword>
	<keyword>atorvastatin</keyword>
	<keyword>immune exhaustion</keyword>
	<keyword>adult</keyword>
	<keyword>Africa</keyword>
</DOC>